113 319

Cited 0 times in

Loperamide overcomes the resistance of colon cancer cells to bortezomib by inducing CHOP-mediated paraptosis-like cell death

DC Field Value Language
dc.contributor.authorKim, IY-
dc.contributor.authorShim, MJ-
dc.contributor.authorLee, DM-
dc.contributor.authorLee, AR-
dc.contributor.authorKim, MA-
dc.contributor.authorYoon, MJ-
dc.contributor.authorKwon, MR-
dc.contributor.authorLee, HI-
dc.contributor.authorSeo, MJ-
dc.contributor.authorChoi, YW-
dc.contributor.authorChoi, KS-
dc.date.accessioned2020-11-17T05:25:17Z-
dc.date.available2020-11-17T05:25:17Z-
dc.date.issued2019-
dc.identifier.issn0006-2952-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/19050-
dc.description.abstractAlthough the proteasome inhibitor (PI) bortezomib (Btz) is in current clinical use as a front-line treatment for multiple myeloma, its clinical efficacy in solid tumors has not been satisfactory. Here, we show that loperamide (Lop), an antidiarrheal drug, effectively sensitizes various colon cancer cells, but not normal epithelial cells, to PI-mediated cell death. We report that combined treatment with Btz and Lop induces paraptosis-like cell death accompanied by severe endoplasmic reticulum (ER)-derived vacuolation. Furthermore, Lop potentiates Btz-mediated ER stress and ER dilation due to misfolded protein accumulation and Ca(2+) imbalance, leading to CHOP upregulation and subsequent paraptosis-like cell death. Taken together, our results show for the first time that a combined regimen of PI and Lop may provide an effective and safe therapeutic strategy against solid tumors, including colon cancer, by enhancing the sensitivity to PIs and reducing the side effects of such treatment.-
dc.language.isoen-
dc.subject.MESHAntidiarrheals / pharmacology-
dc.subject.MESHAntineoplastic Agents / pharmacology-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols / pharmacology-
dc.subject.MESHApoptosis / drug effects-
dc.subject.MESHApoptosis / physiology-
dc.subject.MESHBortezomib / pharmacology-
dc.subject.MESHCell Death / drug effects-
dc.subject.MESHCell Death / physiology-
dc.subject.MESHColonic Neoplasms / pathology-
dc.subject.MESHCyclophosphamide / pharmacology-
dc.subject.MESHDose-Response Relationship, Drug-
dc.subject.MESHDoxorubicin / pharmacology-
dc.subject.MESHDrug Resistance, Neoplasm / drug effects-
dc.subject.MESHDrug Resistance, Neoplasm / physiology-
dc.subject.MESHHCT116 Cells-
dc.subject.MESHHeLa Cells-
dc.subject.MESHHumans-
dc.subject.MESHLoperamide / pharmacology-
dc.subject.MESHPrednisone / pharmacology-
dc.subject.MESHProteasome Inhibitors / pharmacology-
dc.subject.MESHVincristine / pharmacology-
dc.titleLoperamide overcomes the resistance of colon cancer cells to bortezomib by inducing CHOP-mediated paraptosis-like cell death-
dc.typeArticle-
dc.identifier.pmid30529689-
dc.subject.keywordBortezomib-
dc.subject.keywordCHOP-
dc.subject.keywordER stress-
dc.subject.keywordLoperamide-
dc.subject.keywordParaptosis-like cell death-
dc.contributor.affiliatedAuthor최, 용원-
dc.contributor.affiliatedAuthor최, 경숙-
dc.type.localJournal Papers-
dc.identifier.doi10.1016/j.bcp.2018.12.006-
dc.citation.titleBiochemical pharmacology-
dc.citation.volume162-
dc.citation.date2019-
dc.citation.startPage41-
dc.citation.endPage54-
dc.identifier.bibliographicCitationBiochemical pharmacology, 162. : 41-54, 2019-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1873-2968-
dc.relation.journalidJ000062952-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Biochemistry & Molecular Biology
Files in This Item:
30529689.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse